Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.5 USD | +0.13% | -1.59% | +44.86% |
May. 02 | Immunome, Inc. Appoints Kinney Horn as Chief Business Officer | CI |
Apr. 30 | JPMorgan Starts Immunome With Overweight Rating, $24 Price Target | MT |
Financials (USD)
Sales 2024 * | 9.6M | Sales 2025 * | 3.2M | Capitalization | 929M |
---|---|---|---|---|---|
Net income 2024 * | -104M | Net income 2025 * | -144M | EV / Sales 2024 * | 96.8 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 290 x |
P/E ratio 2024 * |
-8.58
x | P/E ratio 2025 * |
-6.9
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.08% |
1 day | +0.13% | ||
1 week | -1.59% | ||
Current month | +10.24% | ||
1 month | -24.68% | ||
3 months | -33.90% | ||
6 months | +91.59% | ||
Current year | +44.86% |
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-10-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | Jan. 01 |
Director/Board Member | 70 | Nov. 06 | |
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 15.5 | +0.13% | 1,046,784 |
24-05-09 | 15.48 | -1.40% | 344,517 |
24-05-08 | 15.7 | +2.41% | 505,028 |
24-05-07 | 15.33 | -0.84% | 342,932 |
24-05-06 | 15.46 | -1.84% | 492,494 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.86% | 929M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- IMNM Stock